Moderna (NASDAQ: MRNA)
Moderna Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Moderna Company Info
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA).
News & Analysis
Is Moderna Stock a Buy?
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over
Moderna EPS Beats Estimates, Sales Rise
Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its newer vaccine sales.
Is It Time to Buy September's Worst-Performing S&P 500 Stocks?
Could rebounds be in store for these beaten-down stocks?
3 Surprisingly Underrated Stocks to Buy Right Now
These stocks might look like bad picks. But appearances can be deceiving.
Down 13% in 1 Day, Is Moderna Stock in Trouble?
There's no hope of it recovering to its prior heights anytime soon.
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.
Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-Pandemic Path?
This high flyer has fallen on hard times recently.
Valuation
Podcast Episodes
Microsoft's Gaming Ambitions and COVID-19 Stocks
Microsoft CEO Satya Nadella talked about his company's doubling down on gaming, which should give gamers and investors pause.
Does Moderna's Coronavirus Vaccine Have an Edge?
Moderna has got some promising news on the coronavirus vaccine front.
Why Moderna Stock Is Up
Moderna shares got a boost as the company continued its COVID-19 vaccine trials.
Why Moderna Stock Just Went Up
Encouraging news coming out of biotech regarding its coronavirus vaccine candidate caused its stock to pop.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.